# Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

> **NCT04731740** · PHASE2 · WITHDRAWN · sponsor: **Saint Petersburg State University, Russia**

## Conditions studied

- Metastatic Thyroid Gland Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

## Interventions

- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04731740
- **Lead sponsor:** Saint Petersburg State University, Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-28
- **Primary completion:** 2023-12-28
- **Final completion:** 2023-12-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04731740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04731740, "Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04731740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*